Y-mAbs Acquired by SERB for $8.60 per Share, Shares Surge Over 100%

Y-mAbs Therapeutics has been acquired by SERB Pharmaceuticals for approximately $412 million, with an offer price of $8.60 per share, representing a 105% premium to its closing share price on August 4. The deal includes Y-mAbs' lead asset, DANYELZA, the first FDA-approved treatment for relapsed or refractory high-risk neuroblastoma. Upon closing, Y-mAbs' stock will no longer be listed on the Nasdaq exchange.

SERB Pharmaceuticals has announced the acquisition of Y-mAbs Therapeutics, Inc. for approximately $412 million, representing a 105% premium to Y-mAbs' closing share price on August 4, 2025. The transaction includes Y-mAbs' lead asset, DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for relapsed or refractory high-risk neuroblastoma. Upon closing, Y-mAbs' stock will no longer be listed on the Nasdaq exchange.

The acquisition will be conducted through an all-cash tender offer, with SERB offering $8.60 per share. This offer represents a significant premium to Y-mAbs' share price, reflecting the strategic value of DANYELZA® and the broader potential for growth in the rare oncology market. The transaction is expected to close by the fourth quarter of 2025, subject to customary conditions and regulatory approvals.

SERB, a global specialty pharmaceutical company, has a growing portfolio of medicines for rare emergency medicine, rare diseases, and CBRN preparedness. The acquisition of DANYELZA® broadens SERB's existing Rare Oncology portfolio and furthers its mission of building a leading portfolio of medicines that improve the standard of care for patients globally. Vanessa Wolfeler, Chief Executive Officer of SERB, commented, "DANYELZA is recognized as a critical treatment option for patients and expands the treatment pathways available to providers in an outpatient setting."

The acquisition is a strategic move for SERB, which aims to leverage its global footprint and expertise to expand the reach of DANYELZA® to new markets. Michael Rossi, President, Chief Executive Officer, and a member of the Board of Directors of Y-mAbs, stated, "This transaction is a testament to our team's hard work in building a strong foundation as a commercial organization with a differentiated, FDA-approved product in DANYELZA."

The acquisition is expected to provide significant value to Y-mAbs' stockholders, with the premium offer representing immediate and certain value. The transaction was unanimously approved by the Y-mAbs Board of Directors following a review of strategic alternatives.

References:
[1] https://finance.yahoo.com/news/serb-pharmaceuticals-agrees-acquire-y-123000963.html